CA2342200A1 - Use of certain drugs for treating nerve root injury - Google Patents
Use of certain drugs for treating nerve root injury Download PDFInfo
- Publication number
- CA2342200A1 CA2342200A1 CA002342200A CA2342200A CA2342200A1 CA 2342200 A1 CA2342200 A1 CA 2342200A1 CA 002342200 A CA002342200 A CA 002342200A CA 2342200 A CA2342200 A CA 2342200A CA 2342200 A1 CA2342200 A1 CA 2342200A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- tnf
- active component
- use according
- addition salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-.alpha.
comprising an effective amount of a TNF-.alpha. inhibitor, as well as method for treatment of such disorders, and the use of TNF-.alpha. inhibitors in the preparation of pharmaceutical composition for such treatment.
comprising an effective amount of a TNF-.alpha. inhibitor, as well as method for treatment of such disorders, and the use of TNF-.alpha. inhibitors in the preparation of pharmaceutical composition for such treatment.
Claims (8)
1. Use of a TNF-.alpha. inhibitor selected from the group consisting of metallo proteinase inhibitors excluding methylprenisolone, tetracyclines including chemically modified tetracyclines, quinolones, corticosteroids, thalidomide, lazaroides, pentoxyphyllines, hydroxamic acid derivatives, carbocyclic acids, napthopyrans, soluble cytokine receptors, monoclonal antibodies towards TNF-.alpha., amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, lactoferrin and lactoferrin derived analogous, and melatonin in the form of the base or its addition salt, in the preparation of a pharmaceutical composition for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF-.alpha. and compounds trigged by the liberation of or presence of TNF-.alpha. by inhibiting spinal disk TNF-.alpha..
2. Use according to claim 1, wherein the active component is selected from the group consisting of tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, and chemically modified tetracyclines dedimethylaminotetracycline, in the form of bases or addition salts.
3. Use according to claim 2, wherein the active component is doxycycline.
4. Use according to claim 1, wherein the active component is selected from hydroxamic acid compounds, carbocyclic acids and derivatives, thalidomide, lazaroides, pentoxyphylline, napthopyrans, soluble cytokine receptors, monoclonal antibody towards TNF-.alpha., amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, melatonin in the form of bases or addition salts.
5.Use according to claim 1, wherein the active component is selected from norfloxacine, ofloxacine, ciprofloxacine, gatifloxacine, pefloxacine, lomefloxacine, and temafloxacine in the form of bases or addition salts.
6.Use according to claim 1, wherein the active component is a metallo proteinase inhibitor in the form of base or addition salts.
7.Use according to claim 1, wherein the active component comprises a substance inhibiting a compound trigged by the release of TNF-.alpha., such as interferon-gamma, interleukin-1, and nitrogen oxide (NO) in the form of base or addition salts
8. Method for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF-.alpha. in mammals, including man, comprising the administration of a pharmaceutically effective amount of a TNF-.alpha. inhibitor selected from the group consisting of metallo proteinase inhibitors excluding methylprednisolone, tetracyclines including chemically modified tetracyclines, quinolones, corticosteroids, thalidomide, lazaroides, pentoxyphylline, hydroxamic acid derivatives, carbocyclic acids, napthopyrans, soluble cytokine receptors, monoclonal antibodies towards TNF-.alpha., amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, lactoferrin and lactoferrin derived analogous, and melatonin in the form of the base or its addition salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2714449A CA2714449A1 (en) | 1998-09-25 | 1999-09-23 | Use of certain drugs for treating nerve root injury |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9803276A SE9803276D0 (en) | 1998-09-25 | 1998-09-25 | Use of certain drugs for treating nerve root injury |
SE9803276-6 | 1998-09-25 | ||
SE9803710A SE9803710L (en) | 1998-09-25 | 1998-10-29 | Use of certain substances for the treatment of nerve root damage |
SE9803710-4 | 1998-10-29 | ||
PCT/SE1999/001671 WO2000018409A1 (en) | 1998-09-25 | 1999-09-23 | Use of certain drugs for treating nerve root injury |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2714449A Division CA2714449A1 (en) | 1998-09-25 | 1999-09-23 | Use of certain drugs for treating nerve root injury |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2342200A1 true CA2342200A1 (en) | 2000-04-06 |
CA2342200C CA2342200C (en) | 2010-11-23 |
Family
ID=26663404
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2342200A Expired - Fee Related CA2342200C (en) | 1998-09-25 | 1999-09-23 | Use of certain drugs for treating nerve root injury |
CA2714449A Abandoned CA2714449A1 (en) | 1998-09-25 | 1999-09-23 | Use of certain drugs for treating nerve root injury |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2714449A Abandoned CA2714449A1 (en) | 1998-09-25 | 1999-09-23 | Use of certain drugs for treating nerve root injury |
Country Status (17)
Country | Link |
---|---|
US (4) | US6649589B1 (en) |
EP (3) | EP2324843A1 (en) |
JP (3) | JP4832641B2 (en) |
CN (1) | CN1326351A (en) |
AT (1) | ATE362363T1 (en) |
AU (1) | AU772036B2 (en) |
BR (1) | BR9913926A (en) |
CA (2) | CA2342200C (en) |
CZ (1) | CZ2001983A3 (en) |
DE (1) | DE69936102T2 (en) |
ES (1) | ES2288319T3 (en) |
HU (1) | HUP0103839A3 (en) |
NZ (1) | NZ510122A (en) |
PL (1) | PL347469A1 (en) |
RU (1) | RU2234336C2 (en) |
SE (1) | SE9803710L (en) |
WO (1) | WO2000018409A1 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US7115557B2 (en) | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
SE9803710L (en) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Use of certain substances for the treatment of nerve root damage |
US7906481B2 (en) * | 1998-09-25 | 2011-03-15 | Sciaticon Ab | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus |
US7811990B2 (en) * | 1998-09-25 | 2010-10-12 | Sciaticon Ab | Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus |
US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
USRE45976E1 (en) | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
WO2001045577A2 (en) * | 1999-12-06 | 2001-06-28 | Sdgi Holdings, Inc. | Intervertebral disc treatment devices and methods |
TWI287987B (en) * | 2000-08-14 | 2007-10-11 | Senju Pharma Co | Cytokine inhibitor |
SE0101256D0 (en) * | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of low back pain |
SE0101257D0 (en) * | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of whiplash associated disorder |
SE0101258D0 (en) * | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of low back pain and whiplash associated disorder |
EP2329828A1 (en) * | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of ischaemia |
WO2003053447A1 (en) * | 2001-12-20 | 2003-07-03 | Hanauske-Abel Hartmut M | Treatment for averting or delaying premature delivery |
US20040054414A1 (en) * | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
JP2006515765A (en) | 2002-11-15 | 2006-06-08 | エスディージーアイ・ホールディングス・インコーポレーテッド | Collagen-based materials and methods for treating synovial joints |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
EP1631266B1 (en) * | 2003-05-13 | 2011-03-16 | DePuy Spine, Inc. | A method of treating degenerative disc disease |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
JP2008518924A (en) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
US8236306B2 (en) * | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
CA2862540C (en) | 2005-09-21 | 2018-07-31 | The Regents Of The University Of California | Systems, compositions, and methods for local imaging and treatment of pain |
US20080015465A1 (en) * | 2006-06-15 | 2008-01-17 | Scuderi Gaetano J | Methods for diagnosing and treating pain in the spinal cord |
US8399619B2 (en) | 2006-06-30 | 2013-03-19 | Warsaw Orthopedic, Inc. | Injectable collagen material |
US8118779B2 (en) | 2006-06-30 | 2012-02-21 | Warsaw Orthopedic, Inc. | Collagen delivery device |
WO2008047340A1 (en) * | 2006-10-19 | 2008-04-24 | Mor Research Applications Ltd. | Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders |
US7879894B2 (en) * | 2006-11-28 | 2011-02-01 | Warsaw Orthopedic, Inc. | Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome |
US7709215B2 (en) * | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
WO2009097095A2 (en) * | 2008-01-28 | 2009-08-06 | The Regents Of The University Of California | Methods for treating hematopoietic malignancies |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US9492375B2 (en) | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
US20100226959A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Matrix that prolongs growth factor release |
SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
US8653029B2 (en) | 2009-07-30 | 2014-02-18 | Warsaw Orthopedic, Inc. | Flowable paste and putty bone void filler |
US8597192B2 (en) | 2009-10-30 | 2013-12-03 | Warsaw Orthopedic, Inc. | Ultrasonic devices and methods to diagnose pain generators |
US8722615B2 (en) * | 2009-12-02 | 2014-05-13 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
US8475824B2 (en) * | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
US8758791B2 (en) * | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
US9717779B2 (en) | 2011-01-31 | 2017-08-01 | Warsaw Orthopedic, Inc. | Implantable matrix having optimum ligand concentrations |
EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | Compositions and methods for increasing serum half-life |
US9886546B2 (en) | 2012-11-20 | 2018-02-06 | General Electric Company | Methods and apparatus to label radiology images |
US20160193302A1 (en) * | 2013-09-02 | 2016-07-07 | Nestec S.A. | Lactoferrin and memory and learning speed in children |
WO2016025789A1 (en) * | 2014-08-15 | 2016-02-18 | PixarBio Corporation | Compositions for inhibting inflammation in a subject with a spinal cord injury and methods of using the same |
US20210403416A1 (en) * | 2018-06-13 | 2021-12-30 | Texas Tech University System | Novel Modified Tetracyclines for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US707775A (en) * | 1902-03-22 | 1902-08-26 | Max Huncke Chemical Company | Embalming-catheter. |
US4666897A (en) | 1983-12-29 | 1987-05-19 | Research Foundation Of State University | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
US4925833A (en) | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5686428A (en) * | 1989-04-07 | 1997-11-11 | Aktiebolaget Astra | Pharmaceutical composition |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
JP2818056B2 (en) * | 1990-09-07 | 1998-10-30 | 森永乳業株式会社 | Antimicrobial peptides and antimicrobial agents |
DE4028487A1 (en) | 1990-09-09 | 1992-03-12 | Peter Dr Med Wehling | Interleukin inhibitors of cytokine synthesis - used to treat nerve inflammation, associated pain, spinal injury and slipped disc |
US20060246073A1 (en) * | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US20070298040A1 (en) | 1991-03-18 | 2007-12-27 | Centocor, Inc. | Methods of treating seronegative arthropathy with anti-TNF antibodies |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
EP0525467B1 (en) * | 1991-07-10 | 1997-03-26 | Nippon Steel Corporation | Grain oriented silicon steel sheet having excellent primary glass film properties |
US5763446A (en) * | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
EP0633776B1 (en) * | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
DE4219626A1 (en) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Incorporating therapeutic gene via vector into body cells - in=vivo or in vitro, for subsequent expression and secretion of active protein, partic. for treating degenerative diseases of spine and nerves |
US20050260201A1 (en) * | 1993-01-29 | 2005-11-24 | Centocor, Inc. | Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins |
JP3312946B2 (en) * | 1993-03-04 | 2002-08-12 | 雪印乳業株式会社 | Virus infection / growth inhibitor |
JPH09501918A (en) | 1993-08-12 | 1997-02-25 | アストラ・アクチエボラーグ | Amidine derivative having nitric oxide synthase activity |
US5650396A (en) * | 1994-03-15 | 1997-07-22 | Celtrix Pharmaceuticals, Inc. | Methods of modulating inflammatory cytokines in the CNS using TGF-β |
US5574022A (en) * | 1994-04-14 | 1996-11-12 | The Center For Innovative Technology | Method of attenuating physical damage to the spinal cord |
US5703092A (en) | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
US6001828A (en) * | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
KR970706272A (en) | 1995-08-10 | 1997-11-03 | 클래스 빌헬름슨 | Bicyclic Amidine Derivatives Useful in Therapy < RTI ID = 0.0 > |
SI0891332T1 (en) | 1996-03-29 | 2004-06-30 | Pfizer Inc. | 6-phenylpyridyl-2-amine derivatives |
US6406867B1 (en) * | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
HN1997000027A (en) | 1996-12-06 | 1997-06-05 | Pfizer Prod Inc | DERIVATIVES OF 6-PHENYL PIRIDIL - 2 AMINE |
JP3505189B2 (en) | 1997-02-10 | 2004-03-08 | ファイザー・プロダクツ・インク | 2-amino-6- (2-substituted-4-phenoxy) -substituted pyridine |
US6319910B1 (en) * | 1997-12-19 | 2001-11-20 | Hospital For Joint Diseases | Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha |
WO1999057303A1 (en) * | 1998-05-07 | 1999-11-11 | University Of Maryland, Baltimore | A method for diagnosing and treating chronic pelvic pain syndrome |
US20020132307A1 (en) * | 1998-08-12 | 2002-09-19 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
SE9803710L (en) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Use of certain substances for the treatment of nerve root damage |
US7115557B2 (en) * | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
US20010055594A1 (en) | 1998-09-25 | 2001-12-27 | Kjell Olmarker | Use of certain drugs for treating nerve root injury |
US7906481B2 (en) * | 1998-09-25 | 2011-03-15 | Sciaticon Ab | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus |
US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6419934B1 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
US7629311B2 (en) * | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
US20030113318A1 (en) * | 1999-02-24 | 2003-06-19 | Tobinick Edward Lewis | TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea |
US20030185826A1 (en) * | 1999-02-24 | 2003-10-02 | Tobinick Edward L. | Cytokine antagonists for the treatment of localized disorders |
US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US6537549B2 (en) | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
US6423321B2 (en) | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
US8119127B2 (en) | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
TW555812B (en) * | 1999-12-24 | 2003-10-01 | Sumitomo Chemical Co | Azo-compounds and dye polarizing films containing them |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
EP2329842A3 (en) | 2000-05-12 | 2011-07-27 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
SE0200667D0 (en) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
US7226250B2 (en) * | 2003-12-22 | 2007-06-05 | Hayes Lemmerz International, Inc. | Tool and method for forming a lug hole |
US20050220971A1 (en) * | 2004-04-01 | 2005-10-06 | Katalin Coburn | Process for making non-emulsified, spiced or flavored peanut butters and peanut butter spreads, with lower fat content, long shelf life, and minimal oil separation |
TWI260774B (en) * | 2005-07-19 | 2006-08-21 | Quanta Display Inc | Method for manufacturing liquid crystal display substrates |
-
1998
- 1998-10-29 SE SE9803710A patent/SE9803710L/en not_active Application Discontinuation
-
1999
- 1999-09-23 CA CA2342200A patent/CA2342200C/en not_active Expired - Fee Related
- 1999-09-23 EP EP10181344A patent/EP2324843A1/en not_active Withdrawn
- 1999-09-23 CZ CZ2001983A patent/CZ2001983A3/en unknown
- 1999-09-23 DE DE69936102T patent/DE69936102T2/en not_active Expired - Lifetime
- 1999-09-23 AT AT99952857T patent/ATE362363T1/en active
- 1999-09-23 RU RU2001111322/15A patent/RU2234336C2/en not_active IP Right Cessation
- 1999-09-23 HU HU0103839A patent/HUP0103839A3/en unknown
- 1999-09-23 PL PL99347469A patent/PL347469A1/en unknown
- 1999-09-23 CA CA2714449A patent/CA2714449A1/en not_active Abandoned
- 1999-09-23 EP EP07009705.0A patent/EP1941872B1/en not_active Expired - Lifetime
- 1999-09-23 US US09/743,852 patent/US6649589B1/en not_active Expired - Fee Related
- 1999-09-23 WO PCT/SE1999/001671 patent/WO2000018409A1/en active IP Right Grant
- 1999-09-23 EP EP99952857A patent/EP1115405B1/en not_active Expired - Lifetime
- 1999-09-23 JP JP2000571927A patent/JP4832641B2/en not_active Expired - Fee Related
- 1999-09-23 BR BR9913926-0A patent/BR9913926A/en not_active IP Right Cessation
- 1999-09-23 AU AU64918/99A patent/AU772036B2/en not_active Ceased
- 1999-09-23 ES ES99952857T patent/ES2288319T3/en not_active Expired - Lifetime
- 1999-09-23 CN CN99813548A patent/CN1326351A/en active Pending
- 1999-09-23 NZ NZ510122A patent/NZ510122A/en unknown
-
2001
- 2001-01-17 US US09/760,811 patent/US20010027175A1/en not_active Abandoned
- 2001-01-17 US US09/760,810 patent/US6635250B2/en not_active Expired - Fee Related
-
2008
- 2008-04-14 US US12/102,178 patent/US7723357B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 JP JP2010239148A patent/JP2011052001A/en active Pending
- 2010-11-18 JP JP2010258380A patent/JP2011063608A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2342200A1 (en) | Use of certain drugs for treating nerve root injury | |
RU2001111322A (en) | APPLICATION OF CERTAIN MEDICINES FOR THE TREATMENT OF NERVE ROOT DAMAGE | |
AP1526A (en) | Sertraline salts and sustained-release dosage forms of sertraline. | |
RU2000127020A (en) | DERIVATIVES OF IMIDAZOPIRIDINE, INHIBITING THE SECRETION OF GASTRIC ACID | |
RU94040859A (en) | Oxo- and hydroxy-substituted hydrocarbon aminoderivatives, processes for preparation thereof, pharmaceutical compositions, method of inhibition of retroviral protease, process for treating aids in mammals | |
ES2295609T3 (en) | TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN. | |
DK0766672T3 (en) | Arylsulfonamido-substituted hydroxamic acids as matrix metallopreteinase inhibitors | |
CA2472335A1 (en) | Geranyl compounds | |
CA2369560A1 (en) | Agent for prophylaxis and treatment of liver disease | |
JP2005533766A5 (en) | ||
RU99118221A (en) | AMINOBENZOPHENONES AS INTERLEUKIN INHIBITORS AND TNF (TUMOR NECROSIS FACTOR) INHIBITORS | |
DE69533194D1 (en) | PYRAZOLO (3.4g) CHINOXALINE AS A PDGF RECEPTOR PROTEIN TYROSIN KINASE INHIBITOR | |
KR940703655A (en) | Pharmaceutical Compositions and Methods of Making the Same | |
SK287908B6 (en) | A pharmaceutical combinations comprising combretastatin and an anticancer agent | |
BRPI0405221A (en) | Solid stable medicinal composition for oral administration | |
WO2001030331A3 (en) | Therapeutic compositions including protein kinase c inhibitors | |
IE780217L (en) | 1,3,5-triazine-2,6-dione derivatives | |
PT1121109E (en) | BIPHASIC FORMULATION CONTAINING TRAMADOL | |
RU2007111704A (en) | 4 [(2,4-Dichloro-5-methoxyphenyl) amino] -6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic disease | |
RU2004109817A (en) | AMINOPYRROLEN DERIVATIVES AS ANTI-INFLAMMATORY PRODUCTS | |
JP2006502173A (en) | Use of vanilloid receptor antagonists to treat pain | |
AU639722B2 (en) | Use of arylalkylamides in the treatment of neurodegenerative diseases | |
DE3687945D1 (en) | ((((3-PYRIDINYL) METHYLENE) AMINO) OXY) ALKANIC ACIDS AND ESTERS. | |
RU2008137533A (en) | ORGANIC COMPOUNDS | |
RU99113432A (en) | NEW DERIVATIVES OF PHENANTRIDINIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140923 |